{"gene":"KLRK1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2002,"finding":"NKG2D recruits two distinct adapter molecules depending on cell type: DAP10 (which recruits PI3K) in CD8+ T cells, and DAP12 (which recruits protein tyrosine kinases) in NK cells. In DAP10-deficient mice, CD8+ T cells lack NKG2D expression and cannot mount tumor-specific responses, while NK cells retain functional NKG2D via DAP12 association.","method":"DAP10-deficient mouse model, functional immune assays, receptor-adapter association studies","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with defined cellular phenotype, replicated across cell types with mechanistic explanation","pmids":["12426564"],"is_preprint":false},{"year":2003,"finding":"NKG2D-DAP10 signaling triggers NK cell killing independently of Syk family kinases. A YINM motif in the DAP10 cytoplasmic tail couples receptor stimulation to PI3K, Vav1, Rho family GTPases, and phospholipase C activation.","method":"In vitro kinase assays, signaling pathway dissection with pharmacological inhibitors and dominant-negative constructs","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro mechanistic dissection with mutagenesis of key motif and multiple downstream pathway readouts","pmids":["12740575"],"is_preprint":false},{"year":2001,"finding":"Ectopic expression of murine NKG2D ligands Rae1β or H60 on tumor cells causes potent rejection mediated by NK cells and/or CD8+ T cells in syngeneic mice, directly linking NKG2D ligand expression to tumor cell rejection in vivo.","method":"Tumor transplantation in syngeneic mice, NK/CD8 T cell depletion, in vivo rejection assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean in vivo genetic gain-of-function with cell-depletion controls, highly cited foundational study","pmids":["11557981"],"is_preprint":false},{"year":2007,"finding":"On tumor cell surfaces, MICA associates with ERp5 (PDIA6/P5), a disulfide isomerase. ERp5 forms transitory mixed disulfide complexes with MICA's membrane-proximal alpha3 domain, enabling proteolytic cleavage and shedding of soluble MICA, which promotes tumor immune evasion by inducing NKG2D internalization and degradation.","method":"Co-IP, ERp5 gene silencing, pharmacological inhibition of thioreductase activity, disulfide bond analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (Co-IP, knockdown, pharmacological inhibition) establishing a specific molecular mechanism","pmids":["17495932"],"is_preprint":false},{"year":2006,"finding":"NKG2D costimulation of NKG2D+CD4+ T cells in late-stage tumor settings drives Fas ligand (FasL) production; these NKG2D-costimulated cells are protected from Fas-mediated growth arrest while FasL suppresses proliferation of T cells lacking NKG2D costimulation, revealing a paracrine immunosuppressive mechanism.","method":"In vitro T cell stimulation assays, FasL blocking, peripheral blood NKG2D+CD8+ T cell studies","journal":"Nature immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vitro mechanistic dissection but from a single laboratory","pmids":["16732291"],"is_preprint":false},{"year":2006,"finding":"Soluble ULBP (sULBP) released by tumor cells downregulates surface NKG2D expression on NK cells, reducing NK cell cytotoxicity in an NKG2D-dependent manner; GPI-anchored ULBPs on tumor cells are shed via phospholipase C activity.","method":"NK cell co-culture with tumor supernatants, recombinant ULBP-Fc treatment, PI-PLC inhibition, flow cytometry for NKG2D surface expression, cytotoxicity assays","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional readouts in a single study linking sULBP to NKG2D downregulation and reduced cytotoxicity","pmids":["16630603"],"is_preprint":false},{"year":2009,"finding":"Upon interaction with MICB-expressing target cells, NKG2D and its adapter DAP10 are trafficked to secretory lysosomes; approximately 50% of total NKG2D protein is degraded via lysosomal pathway, while an intracellular pool recycles to the plasma membrane in activated NK cells. DAP10 polarizes to the cytotoxic immune synapse before degradation.","method":"Confocal microscopy, subcellular fractionation, live imaging of NKL cells and primary NK cells, lysosomal inhibitors","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence (receptor degradation after ligand engagement) using multiple imaging approaches","pmids":["19329438"],"is_preprint":false},{"year":2004,"finding":"NKG2D-mediated cytotoxicity and cytokine secretion (IFN-γ, GM-CSF) are counter-regulated by inhibitory Ly49 receptors; Ly49A/G inhibition cannot be overcome even by high H60 expression, whereas Ly49C/I inhibition can be overridden depending on H60 expression levels on target cells.","method":"NK cell cytotoxicity assays, antibody-mediated crosslinking of NKG2D and Ly49 receptors, cytokine ELISA","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — functional epistasis between NKG2D and inhibitory Ly49 receptors with defined readouts","pmids":["15328154"],"is_preprint":false},{"year":2011,"finding":"HMBOX1, a homeobox protein highly expressed in primary human NK cells, negatively regulates NKG2D surface expression and suppresses the NKG2D/DAP10 signaling pathway, reducing NK cell cytotoxicity, CD107a degranulation, and cytolytic protein production.","method":"HMBOX1 overexpression and knockdown in NK cells, flow cytometry for NKG2D expression, cytotoxicity assays, CD107a degranulation assay","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with defined cellular and signaling phenotype","pmids":["21706044"],"is_preprint":false},{"year":2011,"finding":"Co-stimulation of CD8+ T cells through CD3 and NKG2D simultaneously activates β-catenin and induces β-catenin target gene expression, preventing production of anti-inflammatory cytokines (IL-10, IL-9, IL-13, VEGF-α) in a β-catenin- and PPARγ-dependent manner, a signaling outcome not observed with TCR or TCR+CD28 stimulation alone.","method":"Chimeric NKG2D receptor signaling, β-catenin pathway analysis, cytokine measurement, pharmacological inhibition of PPARγ and β-catenin","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — defined molecular pathway (β-catenin activation) with pharmacological validation in a single study","pmids":["21518928"],"is_preprint":false},{"year":2001,"finding":"Pig NKG2D requires DAP10 for cell surface expression; when transiently transfected into COS-7 cells, pig NKG2D only reaches the cell surface in the presence of DAP10, demonstrating a conserved obligate adapter requirement for receptor surface expression.","method":"Transient transfection of COS-7 cells, flow cytometry for surface expression","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 3 — single co-expression experiment demonstrating DAP10 requirement for NKG2D surface expression","pmids":["11398969"],"is_preprint":false},{"year":2015,"finding":"The MICA-129Met isoform binds NKG2D with higher affinity than MICA-129Val, triggers stronger NKG2D signaling (more degranulation and IFN-γ production in NK cells, faster CD8+ T cell costimulation), but also induces faster and stronger NKG2D downregulation from the cell surface, limiting NKG2D-mediated functions at high expression levels.","method":"Allele-specific MICA expression in melanoma cells, NK cell functional assays (degranulation, IFN-γ ELISA), NKG2D surface expression by flow cytometry, patient transplantation outcome data","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with both alleles tested, mechanistic explanation for polymorphism effects on NKG2D signaling strength and receptor downregulation","pmids":["26483398"],"is_preprint":false},{"year":2015,"finding":"The MICA-129Met variant shows higher susceptibility to shedding (more soluble MICA released) and more intracellular retention compared to MICA-129Val, linking the polymorphism to differential plasma membrane expression and proteolytic shedding.","method":"MICA isoform expression in MICA-negative melanoma cells, soluble MICA ELISA, intracellular vs. surface MICA quantification by flow cytometry","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 — direct comparison of both isoforms expressed in isogenic cell context with multiple readouts","pmids":["26585323"],"is_preprint":false},{"year":2014,"finding":"Induction of NKG2D ligand RAE-1 expression by the DNA damage response requires a STING-dependent DNA sensor pathway involving TBK1 and IRF3; cytosolic DNA is detected in RAE-1-expressing lymphoma cell lines, and transfection of DNA into ligand-negative cells is sufficient to induce RAE-1.","method":"STING pathway genetic knockout (Irf3+/- Eμ-Myc mice), DNA transfection into ligand-negative cells, cytosolic DNA detection","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in mouse model plus gain-of-function transfection, mechanistic pathway placement of NKG2D ligand induction","pmids":["24590060"],"is_preprint":false},{"year":2014,"finding":"Surface upregulation of NKG2D ligands (MICA/B and ULBP families) in human epithelial cells in response to UV irradiation, osmotic shock, oxidative stress, and EGF is mediated by EGFR activation, which causes intracellular relocalization of AUF1 proteins that ordinarily destabilize NKG2D ligand mRNAs by targeting a conserved AU-rich element in the 3' UTR of most human NKG2D ligand genes.","method":"EGFR activation/inhibition, AUF1 relocalization studies, mRNA stability assays, clinical EGFR inhibitor treatment, primary human carcinoma analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 — multiple stress conditions tested, defined post-transcriptional mechanism (AUF1/AU-rich element), validated with clinical inhibitors and patient samples","pmids":["24718859"],"is_preprint":false},{"year":2016,"finding":"CBP and p300 acetyltransferases regulate basal and stress-induced NKG2D ligand expression (MICA/B, ULBP2, and mouse RAE-1) on tumor cells; CBP/p300 loss decreases NKG2D ligand surface expression and abrogates NK cell-mediated killing. Mechanistically, CREB is activated and binds NKG2D ligand promoters together with CBP/p300, increasing histone acetylation at these loci.","method":"CBP/p300 knockdown, ChIP for CREB and CBP/p300 at NKG2D-L promoters, histone acetylation assays, NK cell killing assays, Eμ-Myc mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP evidence for direct promoter binding, loss-of-function with functional NK killing readout, in vivo mouse model validation","pmids":["27477692"],"is_preprint":false},{"year":2017,"finding":"In healthy mice, NKG2D is engaged in vivo by RAE-1ε constitutively expressed on lymph node endothelial cells and highly induced on tumor-associated endothelium; this engagement causes NKG2D internalization from NK cell surface and desensitizes NK cell responses globally to acute stimulation, impairing antitumor NK responses in vivo.","method":"In vivo NKG2D engagement studies, NKG2D internalization assays, NK cell functional assays in WT mice, tumor challenge models","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — direct in vivo demonstration of receptor-ligand interaction causing receptor internalization with functional consequence on antitumor responses","pmids":["29231815"],"is_preprint":false},{"year":2019,"finding":"PARP1 represses expression of NKG2D ligands on leukemic stem cells (LSCs); genetic or pharmacologic inhibition of PARP1 induces NKG2DL surface expression on LSCs but not on healthy or pre-leukemic cells, rendering LSCs susceptible to NK cell-mediated killing.","method":"PARP1 genetic knockout and pharmacological inhibition, NKG2DL surface expression by flow cytometry, patient-derived xenotransplant NK cell killing assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological perturbation with defined mechanistic link (PARP1 → NKG2DL repression) and functional NK killing readout in patient-derived models","pmids":["31316209"],"is_preprint":false},{"year":2013,"finding":"NK cell NKG2D engagement by RAE-1ε expressed on murine endothelial cells in vivo causes NKG2D internalization and transmits an NK-intrinsic signal that globally desensitizes NK cells to acute stimulation. Chronic NKG2D engagement leads to reduced responsiveness, demonstrating NKG2D's role in NK cell peripheral tolerance/education.","method":"In vivo receptor engagement, NK cell desensitization assays, NKG2D internalization measurement","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mechanistic finding but partially overlapping with PMID 29231815","pmids":["29231815"],"is_preprint":false},{"year":2013,"finding":"NKG2D-mediated NK cell activation plays a required role in pulmonary ischemia-reperfusion injury; NKG2D ligands are induced on lung endothelial and epithelial cells following IRI, and antibody-mediated NKG2D blockade or NK cell depletion abrogates acute lung injury in mouse models.","method":"NK cell-deficient mice, adoptive NK cell transfer, NKG2D antibody blockade, two IRI mouse models","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and antibody loss-of-function with defined injury phenotype and mechanistic (ligand induction) link","pmids":["33290276"],"is_preprint":false},{"year":2013,"finding":"NKG2D and granzyme B in NK cells are required for HDM-induced allergic pulmonary inflammation; NKG2D-deficient mice resist allergic induction, and adoptive transfer of wild-type NK cells (but not CD3+ cells or granzyme B-deficient NK cells) restores allergic inflammation.","method":"NKG2D-deficient mouse model, adoptive NK cell transfer, granzyme B-deficient NK cells, HDM allergen challenge model","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function plus cell-type-specific adoptive transfer identifying NKG2D and granzyme B as the required effector mechanism","pmids":["24290277"],"is_preprint":false},{"year":2010,"finding":"NKG2D is required for NK cell activation and cytolytic function in response to adenoviral infection; NKG2D ligands are upregulated on accessory cells (dendritic cells, macrophages) upon adenoviral infection, and NKG2D blockade inhibits NK cell activation and delays adenoviral clearance in vivo.","method":"NKG2D antibody blockade, adenoviral infection model in vivo and in vitro, NK cell depletion, NKG2D ligand upregulation analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blockade and ligand induction evidence linking NKG2D to defined antiviral function","pmids":["21076062"],"is_preprint":false}],"current_model":"KLRK1 (NKG2D) is a homodimeric C-type lectin-like activating receptor that functions by associating obligately with adapter proteins DAP10 (which signals via a YINM motif to recruit PI3K, Vav1, Rho GTPases, and PLCγ in a Syk-independent manner) or DAP12 (which recruits protein tyrosine kinases), with the adapter choice determining whether NKG2D acts as a primary activating receptor (NK cells via DAP12) or a costimulatory receptor (T cells via DAP10); it recognizes stress-induced MHC class I-related ligands (MICA/B, ULBPs in humans; Rae-1, H60 in mice) on transformed or infected cells, driving NK and CD8+ T cell cytotoxicity, cytokine production, and tumor rejection, while its surface expression is dynamically regulated by ligand-induced internalization and lysosomal degradation of the NKG2D/DAP10 complex, soluble ligand-mediated downregulation, ERp5-dependent proteolytic shedding of MICA, transcriptional regulation by CBP/p300 acetyltransferases and PARP1, and post-transcriptional regulation via EGFR-dependent AUF1 relocalization."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing that NKG2D ligand expression on tumor cells is sufficient to drive immune rejection resolved the question of whether NKG2D engagement has functional antitumor consequences in vivo.","evidence":"Ectopic Rae1β/H60 expression on syngeneic tumors with NK/CD8 depletion controls in mice","pmids":["11557981"],"confidence":"High","gaps":["Whether endogenous ligand levels on spontaneous tumors suffice for rejection","Relative contributions of NK vs CD8+ T cells in different tumor contexts"]},{"year":2001,"claim":"Demonstrating that NKG2D requires DAP10 for surface expression established an obligate adapter dependency conserved across species.","evidence":"Pig NKG2D/DAP10 co-transfection in COS-7 cells with surface expression by flow cytometry","pmids":["11398969"],"confidence":"Medium","gaps":["Mechanism by which DAP10 retains NKG2D intracellularly in its absence","Whether other adapters can substitute in any context"]},{"year":2002,"claim":"Identifying that NKG2D pairs with DAP10 in CD8+ T cells versus DAP12 in NK cells explained cell-type-specific signaling and resolved why NKG2D functions as a costimulator in T cells but a primary activating receptor in NK cells.","evidence":"DAP10-knockout mice with cell-type-specific functional assays showing selective loss of NKG2D on CD8+ T cells but retention on NK cells via DAP12","pmids":["12426564"],"confidence":"High","gaps":["Whether adapter switching occurs under activation conditions","The stoichiometry of NKG2D–DAP10 vs NKG2D–DAP12 complexes"]},{"year":2003,"claim":"Mapping the DAP10 YINM motif to PI3K, Vav1, Rho GTPases, and PLCγ recruitment — independent of Syk — defined the intracellular signaling cascade linking NKG2D engagement to cytotoxicity.","evidence":"In vitro kinase assays, pharmacological inhibitors, and dominant-negative constructs in NK cells","pmids":["12740575"],"confidence":"High","gaps":["How Vav1/Rho signaling connects to granule polarization","Whether DAP12-associated signaling engages distinct downstream effectors in human NK cells"]},{"year":2004,"claim":"Showing that inhibitory Ly49 receptors can override NKG2D activation in a receptor-specific manner established the hierarchical integration of activating and inhibitory signals at the NK cell level.","evidence":"NK cell cytotoxicity and cytokine assays with antibody crosslinking of NKG2D and individual Ly49 receptors","pmids":["15328154"],"confidence":"Medium","gaps":["Molecular basis for differential dominance among Ly49 family members","Whether human KIR receptors show analogous hierarchies over NKG2D"]},{"year":2006,"claim":"Discovery that soluble ULBPs and soluble MICA shed from tumors downregulate NKG2D surface expression on NK cells identified a major immune evasion mechanism and linked ligand shedding to receptor internalization.","evidence":"NK cell co-culture with tumor supernatants, recombinant ULBP-Fc treatment, flow cytometry, and cytotoxicity assays","pmids":["16630603","16732291"],"confidence":"Medium","gaps":["Quantitative threshold of soluble ligand needed for functional NKG2D loss","Whether soluble and membrane-bound ligands trigger qualitatively different signaling"]},{"year":2007,"claim":"Identifying ERp5 as the disulfide isomerase that enables proteolytic shedding of MICA from tumor cells provided a specific molecular mechanism for soluble MICA generation and a potential therapeutic target.","evidence":"Co-IP, ERp5 knockdown, pharmacological thioreductase inhibition, and disulfide bond analysis on tumor cells","pmids":["17495932"],"confidence":"High","gaps":["Identity of the protease that cleaves MICA after ERp5 action","Whether ERp5 similarly promotes shedding of ULBP ligands"]},{"year":2009,"claim":"Tracking NKG2D/DAP10 to secretory lysosomes after ligand engagement and showing ~50% receptor degradation with partial recycling established the intracellular trafficking pathway governing NKG2D surface dynamics.","evidence":"Confocal and live imaging of NKL and primary NK cells with lysosomal inhibitors and subcellular fractionation","pmids":["19329438"],"confidence":"Medium","gaps":["Molecular machinery directing NKG2D to lysosomes vs recycling endosomes","Whether DAP12-associated NKG2D follows the same degradation pathway"]},{"year":2010,"claim":"Demonstrating NKG2D requirement for NK cell activation during adenoviral infection — through ligand upregulation on dendritic cells and macrophages — extended NKG2D's role beyond tumor surveillance to antiviral immunity.","evidence":"NKG2D antibody blockade and NK cell depletion in adenoviral infection model in vivo","pmids":["21076062"],"confidence":"Medium","gaps":["Which viral factors trigger NKG2D ligand induction on accessory cells","Whether NKG2D-dependent antiviral function extends to non-adenoviral infections in the same tissue"]},{"year":2011,"claim":"Identification of β-catenin activation as a unique downstream output of NKG2D costimulation in CD8+ T cells — suppressing anti-inflammatory cytokines via PPARγ — revealed a signaling branch distinct from TCR/CD28 pathways.","evidence":"Chimeric NKG2D receptor signaling, β-catenin pathway analysis, and pharmacological inhibition","pmids":["21518928"],"confidence":"Medium","gaps":["How DAP10 couples to β-catenin stabilization mechanistically","In vivo relevance of β-catenin-dependent cytokine suppression"]},{"year":2013,"claim":"Demonstrating that NKG2D and granzyme B are required for allergen-induced pulmonary inflammation expanded NKG2D's physiological roles to non-tumor, non-infection tissue injury.","evidence":"NKG2D-deficient mice, adoptive transfer of WT vs granzyme B-deficient NK cells in HDM allergen model","pmids":["24290277"],"confidence":"High","gaps":["Identity of the NKG2D ligand induced on airway cells by HDM","Whether NKG2D-dependent allergic inflammation is granzyme B-mediated in human asthma"]},{"year":2014,"claim":"Placing NKG2D ligand induction downstream of the STING–TBK1–IRF3 cytosolic DNA sensing pathway connected the DNA damage response to innate immune recognition via NKG2D.","evidence":"STING pathway genetic knockout in Eμ-Myc mice, DNA transfection into ligand-negative cells inducing RAE-1","pmids":["24590060"],"confidence":"High","gaps":["Whether STING-dependent induction applies to human NKG2D ligands (MICA/B, ULBPs)","Whether other pattern-recognition pathways converge on NKG2D ligand promoters"]},{"year":2014,"claim":"Discovering that EGFR activation stabilizes NKG2D ligand mRNAs by relocalizing the destabilizing factor AUF1 away from AU-rich 3′ UTR elements defined a post-transcriptional regulatory axis for NKG2D ligand expression in epithelial cells.","evidence":"EGFR activation/inhibition, AUF1 relocalization, mRNA stability assays, validated with clinical EGFR inhibitors and patient carcinoma samples","pmids":["24718859"],"confidence":"High","gaps":["Which kinase downstream of EGFR phosphorylates AUF1 to trigger relocalization","Whether other RNA-binding proteins cooperate with AUF1 in NKG2D ligand mRNA regulation"]},{"year":2015,"claim":"Characterizing the MICA-129 dimorphism showed that higher-affinity NKG2D binding (Met variant) paradoxically limits NKG2D function through faster receptor downregulation and greater MICA shedding, resolving how ligand affinity inversely correlates with sustained signaling.","evidence":"Allele-specific MICA expression in melanoma cells, NK functional assays, soluble MICA ELISA, intracellular MICA quantification","pmids":["26483398","26585323"],"confidence":"High","gaps":["Whether MICA-129 dimorphism affects ERp5-dependent shedding specifically","Structural basis for affinity difference at the NKG2D–MICA interface"]},{"year":2016,"claim":"Identifying CBP/p300 acetyltransferases and CREB as direct transcriptional activators of NKG2D ligand promoters established the epigenetic control layer governing basal and stress-induced ligand expression.","evidence":"ChIP for CREB and CBP/p300 at NKG2D ligand promoters, histone acetylation assays, CBP/p300 knockdown reducing NK killing, Eμ-Myc mouse validation","pmids":["27477692"],"confidence":"High","gaps":["Whether CBP/p300 activity at these promoters is regulated by specific stress kinases","Interplay between CREB/CBP regulation and STING or EGFR pathways"]},{"year":2017,"claim":"Showing that constitutive RAE-1ε on lymph node and tumor endothelium chronically engages NKG2D in vivo, causing internalization and global NK cell desensitization, established NKG2D as a peripheral tolerance/education receptor beyond its activating function.","evidence":"In vivo NKG2D engagement studies, NKG2D internalization, NK cell functional assays, and tumor challenge in WT mice","pmids":["29231815"],"confidence":"High","gaps":["Molecular basis of global desensitization downstream of chronic NKG2D engagement","Whether human endothelium expresses NKG2D ligands constitutively"]},{"year":2019,"claim":"Demonstrating that PARP1 represses NKG2D ligand expression specifically on leukemic stem cells — and that PARP inhibition restores ligand expression and NK killing — identified a targetable epigenetic barrier to NKG2D-mediated immunosurveillance in AML.","evidence":"PARP1 knockout and pharmacological inhibition, NKG2D ligand surface expression, patient-derived xenotransplant NK killing assays","pmids":["31316209"],"confidence":"High","gaps":["Whether PARP1 repression is direct (at ligand promoters) or indirect","Whether PARP inhibitor-induced NKG2D ligand expression persists long-term in patients"]},{"year":null,"claim":"Key unresolved questions include the structural basis for NKG2D adapter switching between DAP10 and DAP12, the protease responsible for MICA cleavage after ERp5 processing, and whether chronic NKG2D engagement on human endothelium contributes to NK cell tolerance in patients.","evidence":"","pmids":[],"confidence":"Low","gaps":["Structural basis of DAP10 vs DAP12 selectivity in the NKG2D transmembrane domain","Identity of the MICA-cleaving protease downstream of ERp5","In vivo relevance of NKG2D-mediated NK tolerance in human tumor microenvironments"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,10,11,16]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,7,20,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,17]}],"complexes":["NKG2D–DAP10 complex","NKG2D–DAP12 complex"],"partners":["HCST","TYROBP","MICA","MICB","ULBP1","RAET1E","H60"],"other_free_text":[]},"mechanistic_narrative":"KLRK1 (NKG2D) is a homodimeric C-type lectin-like activating receptor on NK cells and CD8+ T cells that detects stress-induced ligands (MICA/B, ULBPs, Rae-1, H60) on transformed, infected, or damaged cells to trigger cytotoxicity, cytokine production, and tumor rejection [PMID:11557981, PMID:12426564]. NKG2D requires the adapter DAP10 for surface expression and signals through a YINM motif that recruits PI3K, Vav1, Rho GTPases, and PLCγ independently of Syk kinases; in murine NK cells it can alternatively associate with DAP12 to recruit protein tyrosine kinases, functioning as a primary activating receptor rather than a costimulator [PMID:12426564, PMID:12740575]. Surface NKG2D expression is dynamically regulated by ligand-induced internalization and lysosomal degradation, by soluble ligand shedding (facilitated by ERp5-dependent disulfide isomerization of MICA), and by transcriptional control of its ligands through CBP/p300–CREB, PARP1 repression, STING-dependent DNA sensing, and EGFR–AUF1-mediated mRNA stabilization [PMID:19329438, PMID:17495932, PMID:27477692, PMID:31316209, PMID:24590060, PMID:24718859]. Chronic in vivo engagement of NKG2D by constitutive RAE-1ε on endothelial cells desensitizes NK cells globally, establishing NKG2D as a peripheral tolerance checkpoint [PMID:29231815]."},"prefetch_data":{"uniprot":{"accession":"P26718","full_name":"NKG2-D type II integral membrane protein","aliases":["Killer cell lectin-like receptor subfamily K member 1","NK cell receptor D","NKG2-D-activating NK receptor"],"length_aa":216,"mass_kda":25.3,"function":"Functions as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor cells. Signaling involves calcium influx, culminating in the expression of TNF. Participates in NK cell-mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins including MICA, MICB, RAET1E, RAET1G, RAET1L/ULBP6, ULBP1, ULBP2, ULBP3 (ULBP2>ULBP1>ULBP3) and ULBP4","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P26718/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KLRK1"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KLRK1","total_profiled":1310},"omim":[{"mim_id":"618131","title":"IMMUNODEFICIENCY 58; IMD58","url":"https://www.omim.org/entry/618131"},{"mim_id":"617573","title":"C-TYPE LECTIN DOMAIN FAMILY 12, MEMBER B; CLEC12B","url":"https://www.omim.org/entry/617573"},{"mim_id":"611817","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY K, MEMBER 1; KLRK1","url":"https://www.omim.org/entry/611817"},{"mim_id":"610859","title":"CAPPING PROTEIN REGULATOR AND MYOSIN 1 LINKER 2; CARMIL2","url":"https://www.omim.org/entry/610859"},{"mim_id":"609243","title":"RETINOIC ACID EARLY TRANSCRIPT 1E; RAET1E","url":"https://www.omim.org/entry/609243"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":20.8},{"tissue":"lymphoid tissue","ntpm":39.4}],"url":"https://www.proteinatlas.org/search/KLRK1"},"hgnc":{"alias_symbol":["NKG2D","KLR","NKG2-D","CD314"],"prev_symbol":["D12S2489E"]},"alphafold":{"accession":"P26718","domains":[{"cath_id":"3.10.100.10","chopping":"105-215","consensus_level":"high","plddt":96.0536,"start":105,"end":215}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P26718","model_url":"https://alphafold.ebi.ac.uk/files/AF-P26718-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P26718-F1-predicted_aligned_error_v6.png","plddt_mean":79.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KLRK1","jax_strain_url":"https://www.jax.org/strain/search?query=KLRK1"},"sequence":{"accession":"P26718","fasta_url":"https://rest.uniprot.org/uniprotkb/P26718.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P26718/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P26718"}},"corpus_meta":[{"pmid":"14523385","id":"PMC_14523385","title":"Roles of the NKG2D immunoreceptor and its ligands.","date":"2003","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14523385","citation_count":1038,"is_preprint":false},{"pmid":"11557981","id":"PMC_11557981","title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11557981","citation_count":753,"is_preprint":false},{"pmid":"23298206","id":"PMC_23298206","title":"Regulation of ligands for the NKG2D activating receptor.","date":"2013","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23298206","citation_count":680,"is_preprint":false},{"pmid":"12714493","id":"PMC_12714493","title":"Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12714493","citation_count":430,"is_preprint":false},{"pmid":"20536569","id":"PMC_20536569","title":"Effect of NKG2D ligand expression on host immune responses.","date":"2010","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20536569","citation_count":401,"is_preprint":false},{"pmid":"12426564","id":"PMC_12426564","title":"NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12426564","citation_count":322,"is_preprint":false},{"pmid":"17495932","id":"PMC_17495932","title":"Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17495932","citation_count":302,"is_preprint":false},{"pmid":"31316209","id":"PMC_31316209","title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31316209","citation_count":300,"is_preprint":false},{"pmid":"17673918","id":"PMC_17673918","title":"Promiscuity and the single receptor: NKG2D.","date":"2007","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17673918","citation_count":297,"is_preprint":false},{"pmid":"12740575","id":"PMC_12740575","title":"NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12740575","citation_count":278,"is_preprint":false},{"pmid":"29568297","id":"PMC_29568297","title":"NKG2D: A Master Regulator of Immune Cell Responsiveness.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29568297","citation_count":220,"is_preprint":false},{"pmid":"15548365","id":"PMC_15548365","title":"Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.","date":"2004","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15548365","citation_count":212,"is_preprint":false},{"pmid":"29662484","id":"PMC_29662484","title":"NKG2D and Its Ligands: \"One for All, All for One\".","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29662484","citation_count":204,"is_preprint":false},{"pmid":"29525346","id":"PMC_29525346","title":"NKG2D and its ligands in cancer.","date":"2018","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29525346","citation_count":185,"is_preprint":false},{"pmid":"16329186","id":"PMC_16329186","title":"Immunobiology of human NKG2D and its ligands.","date":"2006","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16329186","citation_count":166,"is_preprint":false},{"pmid":"23679194","id":"PMC_23679194","title":"Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.","date":"2013","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23679194","citation_count":156,"is_preprint":false},{"pmid":"11973127","id":"PMC_11973127","title":"Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?","date":"2002","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11973127","citation_count":149,"is_preprint":false},{"pmid":"24590060","id":"PMC_24590060","title":"RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24590060","citation_count":145,"is_preprint":false},{"pmid":"37585504","id":"PMC_37585504","title":"NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37585504","citation_count":143,"is_preprint":false},{"pmid":"31720075","id":"PMC_31720075","title":"Role of NKG2D and its ligands in cancer immunotherapy.","date":"2019","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31720075","citation_count":140,"is_preprint":false},{"pmid":"30254634","id":"PMC_30254634","title":"NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30254634","citation_count":138,"is_preprint":false},{"pmid":"16732291","id":"PMC_16732291","title":"Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16732291","citation_count":132,"is_preprint":false},{"pmid":"31803194","id":"PMC_31803194","title":"Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31803194","citation_count":123,"is_preprint":false},{"pmid":"31484657","id":"PMC_31484657","title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31484657","citation_count":122,"is_preprint":false},{"pmid":"29400704","id":"PMC_29400704","title":"Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29400704","citation_count":121,"is_preprint":false},{"pmid":"17614877","id":"PMC_17614877","title":"Regulation of ligands for the activating receptor NKG2D.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17614877","citation_count":120,"is_preprint":false},{"pmid":"15885603","id":"PMC_15885603","title":"Exosomes and the MICA-NKG2D system in cancer.","date":"2005","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15885603","citation_count":120,"is_preprint":false},{"pmid":"34394116","id":"PMC_34394116","title":"Leveraging NKG2D Ligands in Immuno-Oncology.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34394116","citation_count":116,"is_preprint":false},{"pmid":"33363734","id":"PMC_33363734","title":"NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells.","date":"2020","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33363734","citation_count":113,"is_preprint":false},{"pmid":"16914326","id":"PMC_16914326","title":"The role of the NKG2D receptor for tumor immunity.","date":"2006","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/16914326","citation_count":107,"is_preprint":false},{"pmid":"18508446","id":"PMC_18508446","title":"Soluble NKG2D ligands: prevalence, release, and functional impact.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/18508446","citation_count":104,"is_preprint":false},{"pmid":"29162646","id":"PMC_29162646","title":"NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29162646","citation_count":102,"is_preprint":false},{"pmid":"24353908","id":"PMC_24353908","title":"New prospects on the NKG2D/NKG2DL system for oncology.","date":"2013","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/24353908","citation_count":102,"is_preprint":false},{"pmid":"29769244","id":"PMC_29769244","title":"A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.","date":"2018","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29769244","citation_count":101,"is_preprint":false},{"pmid":"16630603","id":"PMC_16630603","title":"Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.","date":"2006","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16630603","citation_count":99,"is_preprint":false},{"pmid":"16380817","id":"PMC_16380817","title":"NKG2D in NK and T cell-mediated immunity.","date":"2005","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16380817","citation_count":93,"is_preprint":false},{"pmid":"26284473","id":"PMC_26284473","title":"Genetics, genomics, and evolutionary biology of NKG2D ligands.","date":"2015","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26284473","citation_count":92,"is_preprint":false},{"pmid":"28659311","id":"PMC_28659311","title":"Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28659311","citation_count":91,"is_preprint":false},{"pmid":"17109473","id":"PMC_17109473","title":"Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17109473","citation_count":90,"is_preprint":false},{"pmid":"24667963","id":"PMC_24667963","title":"NKG2D CARs as cell therapy for cancer.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/24667963","citation_count":89,"is_preprint":false},{"pmid":"18193361","id":"PMC_18193361","title":"The NKG2D receptor: immunobiology and clinical implications.","date":"2008","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/18193361","citation_count":88,"is_preprint":false},{"pmid":"18353724","id":"PMC_18353724","title":"The NKG2D receptor: sensing stressed cells.","date":"2008","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18353724","citation_count":86,"is_preprint":false},{"pmid":"18316620","id":"PMC_18316620","title":"Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18316620","citation_count":85,"is_preprint":false},{"pmid":"16087327","id":"PMC_16087327","title":"MIC and other NKG2D ligands: from none to too many.","date":"2005","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16087327","citation_count":83,"is_preprint":false},{"pmid":"17510432","id":"PMC_17510432","title":"Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17510432","citation_count":82,"is_preprint":false},{"pmid":"25277195","id":"PMC_25277195","title":"MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25277195","citation_count":82,"is_preprint":false},{"pmid":"30984204","id":"PMC_30984204","title":"NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30984204","citation_count":75,"is_preprint":false},{"pmid":"29231815","id":"PMC_29231815","title":"Endothelial cells express NKG2D ligands and desensitize antitumor NK responses.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29231815","citation_count":73,"is_preprint":false},{"pmid":"19178412","id":"PMC_19178412","title":"Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention.","date":"2009","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/19178412","citation_count":69,"is_preprint":false},{"pmid":"26483398","id":"PMC_26483398","title":"The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.","date":"2015","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26483398","citation_count":69,"is_preprint":false},{"pmid":"25050215","id":"PMC_25050215","title":"Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.","date":"2014","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/25050215","citation_count":67,"is_preprint":false},{"pmid":"21099111","id":"PMC_21099111","title":"Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21099111","citation_count":66,"is_preprint":false},{"pmid":"34604863","id":"PMC_34604863","title":"A summary of current NKG2D-based CAR clinical trials.","date":"2021","source":"Immunotherapy advances","url":"https://pubmed.ncbi.nlm.nih.gov/34604863","citation_count":66,"is_preprint":false},{"pmid":"12593971","id":"PMC_12593971","title":"The NKG2D receptor and its ligands-recognition beyond the \"missing self\"?","date":"2003","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/12593971","citation_count":63,"is_preprint":false},{"pmid":"18599182","id":"PMC_18599182","title":"Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18599182","citation_count":63,"is_preprint":false},{"pmid":"23628805","id":"PMC_23628805","title":"NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.","date":"2013","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23628805","citation_count":62,"is_preprint":false},{"pmid":"34200375","id":"PMC_34200375","title":"NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34200375","citation_count":61,"is_preprint":false},{"pmid":"33290276","id":"PMC_33290276","title":"Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33290276","citation_count":60,"is_preprint":false},{"pmid":"30150983","id":"PMC_30150983","title":"The Paradoxical Role of NKG2D in Cancer Immunity.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30150983","citation_count":55,"is_preprint":false},{"pmid":"24445601","id":"PMC_24445601","title":"Advances in NKG2D ligand recognition and responses by NK cells.","date":"2014","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24445601","citation_count":55,"is_preprint":false},{"pmid":"33484773","id":"PMC_33484773","title":"Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.","date":"2021","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33484773","citation_count":54,"is_preprint":false},{"pmid":"24190430","id":"PMC_24190430","title":"Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24190430","citation_count":53,"is_preprint":false},{"pmid":"19286259","id":"PMC_19286259","title":"The role of the activating receptor NKG2D in autoimmunity.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19286259","citation_count":50,"is_preprint":false},{"pmid":"24711808","id":"PMC_24711808","title":"Molecular Bases for the Regulation of NKG2D Ligands in Cancer.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24711808","citation_count":49,"is_preprint":false},{"pmid":"24718859","id":"PMC_24718859","title":"Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24718859","citation_count":49,"is_preprint":false},{"pmid":"38704364","id":"PMC_38704364","title":"Targeting senescent cells with NKG2D-CAR T cells.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38704364","citation_count":48,"is_preprint":false},{"pmid":"32082316","id":"PMC_32082316","title":"Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32082316","citation_count":48,"is_preprint":false},{"pmid":"23136011","id":"PMC_23136011","title":"Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells.","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23136011","citation_count":48,"is_preprint":false},{"pmid":"27667711","id":"PMC_27667711","title":"Regulation of NKG2D Expression and Signaling by Endocytosis.","date":"2016","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27667711","citation_count":47,"is_preprint":false},{"pmid":"26585323","id":"PMC_26585323","title":"The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA.","date":"2015","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/26585323","citation_count":47,"is_preprint":false},{"pmid":"35565467","id":"PMC_35565467","title":"Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35565467","citation_count":46,"is_preprint":false},{"pmid":"24290277","id":"PMC_24290277","title":"Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24290277","citation_count":45,"is_preprint":false},{"pmid":"19089424","id":"PMC_19089424","title":"TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.","date":"2008","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/19089424","citation_count":44,"is_preprint":false},{"pmid":"25270965","id":"PMC_25270965","title":"MICA SNPs and the NKG2D system in virus-induced HCC.","date":"2014","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25270965","citation_count":43,"is_preprint":false},{"pmid":"30268986","id":"PMC_30268986","title":"IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a.","date":"2018","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30268986","citation_count":43,"is_preprint":false},{"pmid":"15328154","id":"PMC_15328154","title":"NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15328154","citation_count":43,"is_preprint":false},{"pmid":"28018354","id":"PMC_28018354","title":"Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28018354","citation_count":43,"is_preprint":false},{"pmid":"37626965","id":"PMC_37626965","title":"The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37626965","citation_count":38,"is_preprint":false},{"pmid":"19329438","id":"PMC_19329438","title":"The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19329438","citation_count":38,"is_preprint":false},{"pmid":"19081632","id":"PMC_19081632","title":"Murine NKG2D ligands: \"double, double toil and trouble\".","date":"2008","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19081632","citation_count":37,"is_preprint":false},{"pmid":"21518928","id":"PMC_21518928","title":"NKG2D receptor regulates human effector T-cell cytokine production.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21518928","citation_count":37,"is_preprint":false},{"pmid":"22641658","id":"PMC_22641658","title":"Cancer immunotherapy using NKG2D and DNAM-1 systems.","date":"2012","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22641658","citation_count":36,"is_preprint":false},{"pmid":"32349046","id":"PMC_32349046","title":"BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.","date":"2020","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/32349046","citation_count":35,"is_preprint":false},{"pmid":"18400193","id":"PMC_18400193","title":"Cancer immunosurveillance: NKG2D breaks cover.","date":"2008","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18400193","citation_count":34,"is_preprint":false},{"pmid":"33508619","id":"PMC_33508619","title":"Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33508619","citation_count":33,"is_preprint":false},{"pmid":"18259774","id":"PMC_18259774","title":"Murine cytomegalovirus regulation of NKG2D ligands.","date":"2008","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18259774","citation_count":33,"is_preprint":false},{"pmid":"21706044","id":"PMC_21706044","title":"HMBOX1 negatively regulates NK cell functions by suppressing the NKG2D/DAP10 signaling pathway.","date":"2011","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21706044","citation_count":32,"is_preprint":false},{"pmid":"28443092","id":"PMC_28443092","title":"Disarming Cellular Alarm Systems-Manipulation of Stress-Induced NKG2D Ligands by Human Herpesviruses.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28443092","citation_count":31,"is_preprint":false},{"pmid":"16091471","id":"PMC_16091471","title":"NKG2D-independent suppression of T cell proliferation by H60 and MICA.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16091471","citation_count":29,"is_preprint":false},{"pmid":"32075046","id":"PMC_32075046","title":"Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32075046","citation_count":28,"is_preprint":false},{"pmid":"18979514","id":"PMC_18979514","title":"Viral inhibitors of NKG2D ligands: friends or foes of immune surveillance?","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18979514","citation_count":28,"is_preprint":false},{"pmid":"29316666","id":"PMC_29316666","title":"Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29316666","citation_count":26,"is_preprint":false},{"pmid":"27783394","id":"PMC_27783394","title":"Association of NKG2D gene variants with susceptibility and severity of rheumatoid arthritis.","date":"2016","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27783394","citation_count":26,"is_preprint":false},{"pmid":"11398969","id":"PMC_11398969","title":"Molecular cloning and characterization of pig immunoreceptor DAP10 and NKG2D.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11398969","citation_count":26,"is_preprint":false},{"pmid":"22843249","id":"PMC_22843249","title":"Immunogenetics of the NKG2D ligand gene family.","date":"2012","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22843249","citation_count":26,"is_preprint":false},{"pmid":"27477692","id":"PMC_27477692","title":"CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27477692","citation_count":25,"is_preprint":false},{"pmid":"37165468","id":"PMC_37165468","title":"Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors.","date":"2023","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/37165468","citation_count":25,"is_preprint":false},{"pmid":"21076062","id":"PMC_21076062","title":"NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21076062","citation_count":25,"is_preprint":false},{"pmid":"15914316","id":"PMC_15914316","title":"Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?","date":"2005","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15914316","citation_count":23,"is_preprint":false},{"pmid":"29209320","id":"PMC_29209320","title":"How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29209320","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41350,"output_tokens":5358,"usd":0.10221},"stage2":{"model":"claude-opus-4-6","input_tokens":8959,"output_tokens":4114,"usd":0.221468},"total_usd":0.323678,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"NKG2D recruits two distinct adapter molecules depending on cell type: DAP10 (which recruits PI3K) in CD8+ T cells, and DAP12 (which recruits protein tyrosine kinases) in NK cells. In DAP10-deficient mice, CD8+ T cells lack NKG2D expression and cannot mount tumor-specific responses, while NK cells retain functional NKG2D via DAP12 association.\",\n      \"method\": \"DAP10-deficient mouse model, functional immune assays, receptor-adapter association studies\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined cellular phenotype, replicated across cell types with mechanistic explanation\",\n      \"pmids\": [\"12426564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NKG2D-DAP10 signaling triggers NK cell killing independently of Syk family kinases. A YINM motif in the DAP10 cytoplasmic tail couples receptor stimulation to PI3K, Vav1, Rho family GTPases, and phospholipase C activation.\",\n      \"method\": \"In vitro kinase assays, signaling pathway dissection with pharmacological inhibitors and dominant-negative constructs\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mechanistic dissection with mutagenesis of key motif and multiple downstream pathway readouts\",\n      \"pmids\": [\"12740575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Ectopic expression of murine NKG2D ligands Rae1β or H60 on tumor cells causes potent rejection mediated by NK cells and/or CD8+ T cells in syngeneic mice, directly linking NKG2D ligand expression to tumor cell rejection in vivo.\",\n      \"method\": \"Tumor transplantation in syngeneic mice, NK/CD8 T cell depletion, in vivo rejection assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo genetic gain-of-function with cell-depletion controls, highly cited foundational study\",\n      \"pmids\": [\"11557981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"On tumor cell surfaces, MICA associates with ERp5 (PDIA6/P5), a disulfide isomerase. ERp5 forms transitory mixed disulfide complexes with MICA's membrane-proximal alpha3 domain, enabling proteolytic cleavage and shedding of soluble MICA, which promotes tumor immune evasion by inducing NKG2D internalization and degradation.\",\n      \"method\": \"Co-IP, ERp5 gene silencing, pharmacological inhibition of thioreductase activity, disulfide bond analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (Co-IP, knockdown, pharmacological inhibition) establishing a specific molecular mechanism\",\n      \"pmids\": [\"17495932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKG2D costimulation of NKG2D+CD4+ T cells in late-stage tumor settings drives Fas ligand (FasL) production; these NKG2D-costimulated cells are protected from Fas-mediated growth arrest while FasL suppresses proliferation of T cells lacking NKG2D costimulation, revealing a paracrine immunosuppressive mechanism.\",\n      \"method\": \"In vitro T cell stimulation assays, FasL blocking, peripheral blood NKG2D+CD8+ T cell studies\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro mechanistic dissection but from a single laboratory\",\n      \"pmids\": [\"16732291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Soluble ULBP (sULBP) released by tumor cells downregulates surface NKG2D expression on NK cells, reducing NK cell cytotoxicity in an NKG2D-dependent manner; GPI-anchored ULBPs on tumor cells are shed via phospholipase C activity.\",\n      \"method\": \"NK cell co-culture with tumor supernatants, recombinant ULBP-Fc treatment, PI-PLC inhibition, flow cytometry for NKG2D surface expression, cytotoxicity assays\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts in a single study linking sULBP to NKG2D downregulation and reduced cytotoxicity\",\n      \"pmids\": [\"16630603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Upon interaction with MICB-expressing target cells, NKG2D and its adapter DAP10 are trafficked to secretory lysosomes; approximately 50% of total NKG2D protein is degraded via lysosomal pathway, while an intracellular pool recycles to the plasma membrane in activated NK cells. DAP10 polarizes to the cytotoxic immune synapse before degradation.\",\n      \"method\": \"Confocal microscopy, subcellular fractionation, live imaging of NKL cells and primary NK cells, lysosomal inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence (receptor degradation after ligand engagement) using multiple imaging approaches\",\n      \"pmids\": [\"19329438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NKG2D-mediated cytotoxicity and cytokine secretion (IFN-γ, GM-CSF) are counter-regulated by inhibitory Ly49 receptors; Ly49A/G inhibition cannot be overcome even by high H60 expression, whereas Ly49C/I inhibition can be overridden depending on H60 expression levels on target cells.\",\n      \"method\": \"NK cell cytotoxicity assays, antibody-mediated crosslinking of NKG2D and Ly49 receptors, cytokine ELISA\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional epistasis between NKG2D and inhibitory Ly49 receptors with defined readouts\",\n      \"pmids\": [\"15328154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HMBOX1, a homeobox protein highly expressed in primary human NK cells, negatively regulates NKG2D surface expression and suppresses the NKG2D/DAP10 signaling pathway, reducing NK cell cytotoxicity, CD107a degranulation, and cytolytic protein production.\",\n      \"method\": \"HMBOX1 overexpression and knockdown in NK cells, flow cytometry for NKG2D expression, cytotoxicity assays, CD107a degranulation assay\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with defined cellular and signaling phenotype\",\n      \"pmids\": [\"21706044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Co-stimulation of CD8+ T cells through CD3 and NKG2D simultaneously activates β-catenin and induces β-catenin target gene expression, preventing production of anti-inflammatory cytokines (IL-10, IL-9, IL-13, VEGF-α) in a β-catenin- and PPARγ-dependent manner, a signaling outcome not observed with TCR or TCR+CD28 stimulation alone.\",\n      \"method\": \"Chimeric NKG2D receptor signaling, β-catenin pathway analysis, cytokine measurement, pharmacological inhibition of PPARγ and β-catenin\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular pathway (β-catenin activation) with pharmacological validation in a single study\",\n      \"pmids\": [\"21518928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Pig NKG2D requires DAP10 for cell surface expression; when transiently transfected into COS-7 cells, pig NKG2D only reaches the cell surface in the presence of DAP10, demonstrating a conserved obligate adapter requirement for receptor surface expression.\",\n      \"method\": \"Transient transfection of COS-7 cells, flow cytometry for surface expression\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single co-expression experiment demonstrating DAP10 requirement for NKG2D surface expression\",\n      \"pmids\": [\"11398969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The MICA-129Met isoform binds NKG2D with higher affinity than MICA-129Val, triggers stronger NKG2D signaling (more degranulation and IFN-γ production in NK cells, faster CD8+ T cell costimulation), but also induces faster and stronger NKG2D downregulation from the cell surface, limiting NKG2D-mediated functions at high expression levels.\",\n      \"method\": \"Allele-specific MICA expression in melanoma cells, NK cell functional assays (degranulation, IFN-γ ELISA), NKG2D surface expression by flow cytometry, patient transplantation outcome data\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with both alleles tested, mechanistic explanation for polymorphism effects on NKG2D signaling strength and receptor downregulation\",\n      \"pmids\": [\"26483398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The MICA-129Met variant shows higher susceptibility to shedding (more soluble MICA released) and more intracellular retention compared to MICA-129Val, linking the polymorphism to differential plasma membrane expression and proteolytic shedding.\",\n      \"method\": \"MICA isoform expression in MICA-negative melanoma cells, soluble MICA ELISA, intracellular vs. surface MICA quantification by flow cytometry\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct comparison of both isoforms expressed in isogenic cell context with multiple readouts\",\n      \"pmids\": [\"26585323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Induction of NKG2D ligand RAE-1 expression by the DNA damage response requires a STING-dependent DNA sensor pathway involving TBK1 and IRF3; cytosolic DNA is detected in RAE-1-expressing lymphoma cell lines, and transfection of DNA into ligand-negative cells is sufficient to induce RAE-1.\",\n      \"method\": \"STING pathway genetic knockout (Irf3+/- Eμ-Myc mice), DNA transfection into ligand-negative cells, cytosolic DNA detection\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in mouse model plus gain-of-function transfection, mechanistic pathway placement of NKG2D ligand induction\",\n      \"pmids\": [\"24590060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Surface upregulation of NKG2D ligands (MICA/B and ULBP families) in human epithelial cells in response to UV irradiation, osmotic shock, oxidative stress, and EGF is mediated by EGFR activation, which causes intracellular relocalization of AUF1 proteins that ordinarily destabilize NKG2D ligand mRNAs by targeting a conserved AU-rich element in the 3' UTR of most human NKG2D ligand genes.\",\n      \"method\": \"EGFR activation/inhibition, AUF1 relocalization studies, mRNA stability assays, clinical EGFR inhibitor treatment, primary human carcinoma analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple stress conditions tested, defined post-transcriptional mechanism (AUF1/AU-rich element), validated with clinical inhibitors and patient samples\",\n      \"pmids\": [\"24718859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CBP and p300 acetyltransferases regulate basal and stress-induced NKG2D ligand expression (MICA/B, ULBP2, and mouse RAE-1) on tumor cells; CBP/p300 loss decreases NKG2D ligand surface expression and abrogates NK cell-mediated killing. Mechanistically, CREB is activated and binds NKG2D ligand promoters together with CBP/p300, increasing histone acetylation at these loci.\",\n      \"method\": \"CBP/p300 knockdown, ChIP for CREB and CBP/p300 at NKG2D-L promoters, histone acetylation assays, NK cell killing assays, Eμ-Myc mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP evidence for direct promoter binding, loss-of-function with functional NK killing readout, in vivo mouse model validation\",\n      \"pmids\": [\"27477692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In healthy mice, NKG2D is engaged in vivo by RAE-1ε constitutively expressed on lymph node endothelial cells and highly induced on tumor-associated endothelium; this engagement causes NKG2D internalization from NK cell surface and desensitizes NK cell responses globally to acute stimulation, impairing antitumor NK responses in vivo.\",\n      \"method\": \"In vivo NKG2D engagement studies, NKG2D internalization assays, NK cell functional assays in WT mice, tumor challenge models\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo demonstration of receptor-ligand interaction causing receptor internalization with functional consequence on antitumor responses\",\n      \"pmids\": [\"29231815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PARP1 represses expression of NKG2D ligands on leukemic stem cells (LSCs); genetic or pharmacologic inhibition of PARP1 induces NKG2DL surface expression on LSCs but not on healthy or pre-leukemic cells, rendering LSCs susceptible to NK cell-mediated killing.\",\n      \"method\": \"PARP1 genetic knockout and pharmacological inhibition, NKG2DL surface expression by flow cytometry, patient-derived xenotransplant NK cell killing assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological perturbation with defined mechanistic link (PARP1 → NKG2DL repression) and functional NK killing readout in patient-derived models\",\n      \"pmids\": [\"31316209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NK cell NKG2D engagement by RAE-1ε expressed on murine endothelial cells in vivo causes NKG2D internalization and transmits an NK-intrinsic signal that globally desensitizes NK cells to acute stimulation. Chronic NKG2D engagement leads to reduced responsiveness, demonstrating NKG2D's role in NK cell peripheral tolerance/education.\",\n      \"method\": \"In vivo receptor engagement, NK cell desensitization assays, NKG2D internalization measurement\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mechanistic finding but partially overlapping with PMID 29231815\",\n      \"pmids\": [\"29231815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKG2D-mediated NK cell activation plays a required role in pulmonary ischemia-reperfusion injury; NKG2D ligands are induced on lung endothelial and epithelial cells following IRI, and antibody-mediated NKG2D blockade or NK cell depletion abrogates acute lung injury in mouse models.\",\n      \"method\": \"NK cell-deficient mice, adoptive NK cell transfer, NKG2D antibody blockade, two IRI mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and antibody loss-of-function with defined injury phenotype and mechanistic (ligand induction) link\",\n      \"pmids\": [\"33290276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKG2D and granzyme B in NK cells are required for HDM-induced allergic pulmonary inflammation; NKG2D-deficient mice resist allergic induction, and adoptive transfer of wild-type NK cells (but not CD3+ cells or granzyme B-deficient NK cells) restores allergic inflammation.\",\n      \"method\": \"NKG2D-deficient mouse model, adoptive NK cell transfer, granzyme B-deficient NK cells, HDM allergen challenge model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function plus cell-type-specific adoptive transfer identifying NKG2D and granzyme B as the required effector mechanism\",\n      \"pmids\": [\"24290277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NKG2D is required for NK cell activation and cytolytic function in response to adenoviral infection; NKG2D ligands are upregulated on accessory cells (dendritic cells, macrophages) upon adenoviral infection, and NKG2D blockade inhibits NK cell activation and delays adenoviral clearance in vivo.\",\n      \"method\": \"NKG2D antibody blockade, adenoviral infection model in vivo and in vitro, NK cell depletion, NKG2D ligand upregulation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade and ligand induction evidence linking NKG2D to defined antiviral function\",\n      \"pmids\": [\"21076062\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KLRK1 (NKG2D) is a homodimeric C-type lectin-like activating receptor that functions by associating obligately with adapter proteins DAP10 (which signals via a YINM motif to recruit PI3K, Vav1, Rho GTPases, and PLCγ in a Syk-independent manner) or DAP12 (which recruits protein tyrosine kinases), with the adapter choice determining whether NKG2D acts as a primary activating receptor (NK cells via DAP12) or a costimulatory receptor (T cells via DAP10); it recognizes stress-induced MHC class I-related ligands (MICA/B, ULBPs in humans; Rae-1, H60 in mice) on transformed or infected cells, driving NK and CD8+ T cell cytotoxicity, cytokine production, and tumor rejection, while its surface expression is dynamically regulated by ligand-induced internalization and lysosomal degradation of the NKG2D/DAP10 complex, soluble ligand-mediated downregulation, ERp5-dependent proteolytic shedding of MICA, transcriptional regulation by CBP/p300 acetyltransferases and PARP1, and post-transcriptional regulation via EGFR-dependent AUF1 relocalization.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KLRK1 (NKG2D) is a homodimeric C-type lectin-like activating receptor on NK cells and CD8+ T cells that detects stress-induced ligands (MICA/B, ULBPs, Rae-1, H60) on transformed, infected, or damaged cells to trigger cytotoxicity, cytokine production, and tumor rejection [PMID:11557981, PMID:12426564]. NKG2D requires the adapter DAP10 for surface expression and signals through a YINM motif that recruits PI3K, Vav1, Rho GTPases, and PLCγ independently of Syk kinases; in murine NK cells it can alternatively associate with DAP12 to recruit protein tyrosine kinases, functioning as a primary activating receptor rather than a costimulator [PMID:12426564, PMID:12740575]. Surface NKG2D expression is dynamically regulated by ligand-induced internalization and lysosomal degradation, by soluble ligand shedding (facilitated by ERp5-dependent disulfide isomerization of MICA), and by transcriptional control of its ligands through CBP/p300–CREB, PARP1 repression, STING-dependent DNA sensing, and EGFR–AUF1-mediated mRNA stabilization [PMID:19329438, PMID:17495932, PMID:27477692, PMID:31316209, PMID:24590060, PMID:24718859]. Chronic in vivo engagement of NKG2D by constitutive RAE-1ε on endothelial cells desensitizes NK cells globally, establishing NKG2D as a peripheral tolerance checkpoint [PMID:29231815].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that NKG2D ligand expression on tumor cells is sufficient to drive immune rejection resolved the question of whether NKG2D engagement has functional antitumor consequences in vivo.\",\n      \"evidence\": \"Ectopic Rae1β/H60 expression on syngeneic tumors with NK/CD8 depletion controls in mice\",\n      \"pmids\": [\"11557981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous ligand levels on spontaneous tumors suffice for rejection\", \"Relative contributions of NK vs CD8+ T cells in different tumor contexts\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that NKG2D requires DAP10 for surface expression established an obligate adapter dependency conserved across species.\",\n      \"evidence\": \"Pig NKG2D/DAP10 co-transfection in COS-7 cells with surface expression by flow cytometry\",\n      \"pmids\": [\"11398969\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which DAP10 retains NKG2D intracellularly in its absence\", \"Whether other adapters can substitute in any context\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying that NKG2D pairs with DAP10 in CD8+ T cells versus DAP12 in NK cells explained cell-type-specific signaling and resolved why NKG2D functions as a costimulator in T cells but a primary activating receptor in NK cells.\",\n      \"evidence\": \"DAP10-knockout mice with cell-type-specific functional assays showing selective loss of NKG2D on CD8+ T cells but retention on NK cells via DAP12\",\n      \"pmids\": [\"12426564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether adapter switching occurs under activation conditions\", \"The stoichiometry of NKG2D–DAP10 vs NKG2D–DAP12 complexes\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping the DAP10 YINM motif to PI3K, Vav1, Rho GTPases, and PLCγ recruitment — independent of Syk — defined the intracellular signaling cascade linking NKG2D engagement to cytotoxicity.\",\n      \"evidence\": \"In vitro kinase assays, pharmacological inhibitors, and dominant-negative constructs in NK cells\",\n      \"pmids\": [\"12740575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Vav1/Rho signaling connects to granule polarization\", \"Whether DAP12-associated signaling engages distinct downstream effectors in human NK cells\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing that inhibitory Ly49 receptors can override NKG2D activation in a receptor-specific manner established the hierarchical integration of activating and inhibitory signals at the NK cell level.\",\n      \"evidence\": \"NK cell cytotoxicity and cytokine assays with antibody crosslinking of NKG2D and individual Ly49 receptors\",\n      \"pmids\": [\"15328154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for differential dominance among Ly49 family members\", \"Whether human KIR receptors show analogous hierarchies over NKG2D\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that soluble ULBPs and soluble MICA shed from tumors downregulate NKG2D surface expression on NK cells identified a major immune evasion mechanism and linked ligand shedding to receptor internalization.\",\n      \"evidence\": \"NK cell co-culture with tumor supernatants, recombinant ULBP-Fc treatment, flow cytometry, and cytotoxicity assays\",\n      \"pmids\": [\"16630603\", \"16732291\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative threshold of soluble ligand needed for functional NKG2D loss\", \"Whether soluble and membrane-bound ligands trigger qualitatively different signaling\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying ERp5 as the disulfide isomerase that enables proteolytic shedding of MICA from tumor cells provided a specific molecular mechanism for soluble MICA generation and a potential therapeutic target.\",\n      \"evidence\": \"Co-IP, ERp5 knockdown, pharmacological thioreductase inhibition, and disulfide bond analysis on tumor cells\",\n      \"pmids\": [\"17495932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protease that cleaves MICA after ERp5 action\", \"Whether ERp5 similarly promotes shedding of ULBP ligands\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Tracking NKG2D/DAP10 to secretory lysosomes after ligand engagement and showing ~50% receptor degradation with partial recycling established the intracellular trafficking pathway governing NKG2D surface dynamics.\",\n      \"evidence\": \"Confocal and live imaging of NKL and primary NK cells with lysosomal inhibitors and subcellular fractionation\",\n      \"pmids\": [\"19329438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular machinery directing NKG2D to lysosomes vs recycling endosomes\", \"Whether DAP12-associated NKG2D follows the same degradation pathway\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating NKG2D requirement for NK cell activation during adenoviral infection — through ligand upregulation on dendritic cells and macrophages — extended NKG2D's role beyond tumor surveillance to antiviral immunity.\",\n      \"evidence\": \"NKG2D antibody blockade and NK cell depletion in adenoviral infection model in vivo\",\n      \"pmids\": [\"21076062\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which viral factors trigger NKG2D ligand induction on accessory cells\", \"Whether NKG2D-dependent antiviral function extends to non-adenoviral infections in the same tissue\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of β-catenin activation as a unique downstream output of NKG2D costimulation in CD8+ T cells — suppressing anti-inflammatory cytokines via PPARγ — revealed a signaling branch distinct from TCR/CD28 pathways.\",\n      \"evidence\": \"Chimeric NKG2D receptor signaling, β-catenin pathway analysis, and pharmacological inhibition\",\n      \"pmids\": [\"21518928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How DAP10 couples to β-catenin stabilization mechanistically\", \"In vivo relevance of β-catenin-dependent cytokine suppression\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that NKG2D and granzyme B are required for allergen-induced pulmonary inflammation expanded NKG2D's physiological roles to non-tumor, non-infection tissue injury.\",\n      \"evidence\": \"NKG2D-deficient mice, adoptive transfer of WT vs granzyme B-deficient NK cells in HDM allergen model\",\n      \"pmids\": [\"24290277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the NKG2D ligand induced on airway cells by HDM\", \"Whether NKG2D-dependent allergic inflammation is granzyme B-mediated in human asthma\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placing NKG2D ligand induction downstream of the STING–TBK1–IRF3 cytosolic DNA sensing pathway connected the DNA damage response to innate immune recognition via NKG2D.\",\n      \"evidence\": \"STING pathway genetic knockout in Eμ-Myc mice, DNA transfection into ligand-negative cells inducing RAE-1\",\n      \"pmids\": [\"24590060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STING-dependent induction applies to human NKG2D ligands (MICA/B, ULBPs)\", \"Whether other pattern-recognition pathways converge on NKG2D ligand promoters\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovering that EGFR activation stabilizes NKG2D ligand mRNAs by relocalizing the destabilizing factor AUF1 away from AU-rich 3′ UTR elements defined a post-transcriptional regulatory axis for NKG2D ligand expression in epithelial cells.\",\n      \"evidence\": \"EGFR activation/inhibition, AUF1 relocalization, mRNA stability assays, validated with clinical EGFR inhibitors and patient carcinoma samples\",\n      \"pmids\": [\"24718859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which kinase downstream of EGFR phosphorylates AUF1 to trigger relocalization\", \"Whether other RNA-binding proteins cooperate with AUF1 in NKG2D ligand mRNA regulation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Characterizing the MICA-129 dimorphism showed that higher-affinity NKG2D binding (Met variant) paradoxically limits NKG2D function through faster receptor downregulation and greater MICA shedding, resolving how ligand affinity inversely correlates with sustained signaling.\",\n      \"evidence\": \"Allele-specific MICA expression in melanoma cells, NK functional assays, soluble MICA ELISA, intracellular MICA quantification\",\n      \"pmids\": [\"26483398\", \"26585323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MICA-129 dimorphism affects ERp5-dependent shedding specifically\", \"Structural basis for affinity difference at the NKG2D–MICA interface\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying CBP/p300 acetyltransferases and CREB as direct transcriptional activators of NKG2D ligand promoters established the epigenetic control layer governing basal and stress-induced ligand expression.\",\n      \"evidence\": \"ChIP for CREB and CBP/p300 at NKG2D ligand promoters, histone acetylation assays, CBP/p300 knockdown reducing NK killing, Eμ-Myc mouse validation\",\n      \"pmids\": [\"27477692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CBP/p300 activity at these promoters is regulated by specific stress kinases\", \"Interplay between CREB/CBP regulation and STING or EGFR pathways\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that constitutive RAE-1ε on lymph node and tumor endothelium chronically engages NKG2D in vivo, causing internalization and global NK cell desensitization, established NKG2D as a peripheral tolerance/education receptor beyond its activating function.\",\n      \"evidence\": \"In vivo NKG2D engagement studies, NKG2D internalization, NK cell functional assays, and tumor challenge in WT mice\",\n      \"pmids\": [\"29231815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of global desensitization downstream of chronic NKG2D engagement\", \"Whether human endothelium expresses NKG2D ligands constitutively\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that PARP1 represses NKG2D ligand expression specifically on leukemic stem cells — and that PARP inhibition restores ligand expression and NK killing — identified a targetable epigenetic barrier to NKG2D-mediated immunosurveillance in AML.\",\n      \"evidence\": \"PARP1 knockout and pharmacological inhibition, NKG2D ligand surface expression, patient-derived xenotransplant NK killing assays\",\n      \"pmids\": [\"31316209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP1 repression is direct (at ligand promoters) or indirect\", \"Whether PARP inhibitor-induced NKG2D ligand expression persists long-term in patients\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for NKG2D adapter switching between DAP10 and DAP12, the protease responsible for MICA cleavage after ERp5 processing, and whether chronic NKG2D engagement on human endothelium contributes to NK cell tolerance in patients.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Structural basis of DAP10 vs DAP12 selectivity in the NKG2D transmembrane domain\", \"Identity of the MICA-cleaving protease downstream of ERp5\", \"In vivo relevance of NKG2D-mediated NK tolerance in human tumor microenvironments\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 10, 11, 16]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 7, 20, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 17]}\n    ],\n    \"complexes\": [\n      \"NKG2D–DAP10 complex\",\n      \"NKG2D–DAP12 complex\"\n    ],\n    \"partners\": [\n      \"HCST\",\n      \"TYROBP\",\n      \"MICA\",\n      \"MICB\",\n      \"ULBP1\",\n      \"RAET1E\",\n      \"H60\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}